Someone just paid 14b for a company offering a Muscarinic Receptor Agonist.
That receptor is in the Blarcamesine bag of tricks. How much is it worth when coupled with the S-1R receptor?
All Content and Data provided by Third-Parties — Terms of Use
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BUSINESS WIRE 7:05 AM ET 12/22/2023
Symbol Last Price Change
BMY 51.26down 0 (0%)
KRTX 215.19down 0 (0%)
QUOTES AS OF 04:10:00 PM ET 12/21/2023
Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety
KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in-Disease Treatment for Alzheimer’s Disease Psychosis, with Promise in Additional Neuropsychiatric and Neurodegenerative Indications
KarXT Is Expected to Launch in the U.S. for the Treatment of Schizophrenia in Adults with a Prescription Drug User Fee Act Date of September 26, 2024
Bristol Myers Squibb (BMY) to Host a Conference Call Today at 8:00 a.m. ET
PRINCETON, N.J. & BOSTON--(BUSINESS WIRE)-- Bristol Myers Squibb(BMY) and Karuna Therapeutics, Inc.(KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb(BMY) has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb(BMY) and Karuna Boards of Directors.
All my posts are my opinion only and shouldn’t be used for decisions regarding purchasing or selling.
